(1) Zhang, K.#;Ji, M.#; Lin, S.; Peng, S.; Zhang, Z.; Zhang, M.; Zhang, J.; Zhang,Y.; Wu, D.; Tian, H.; Chen, X.*; Xu, H.*Design, Synthesis and Biological Evaluation of a Novel Photocaged PI3KInhibitor toward Precise Cancer Treatment. J.Med. Chem. 2021, 64, 7331-7340.

(2) Ji, M.#;Wang, D.#; Lin, S., Wang, C.; Li, L.; Zhang, Z.; Jin, J.; Wu, D.;Dong, Y.; Xu, H.*; Lu, D.*; Chen,X.* A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma growth andbrain metastasis in mice models. ActaPharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2021.05.019.

(3) Sun, Y.#;Fu, R.#; Lin, S.; Zhang, J.; Ji, M.; Zhang, Y.; Wu, D.; Zhang, K.;Tian, H.; Zhang, M.; Sheng, L.; Li, Y.; Jin, J.*; Chen, X.*; Xu, H.* Discovery of NewThieno[2,3-d]pyrimidine and Thiazolo[5,4-d]pyrimidine Derivatives as OrallyActive Phosphoinositide 3-Kinase Inhibitors. Bioorg. Med. Chem. 2021,29, 115890.

(4) Du, T.; Lin,S.; Ji, M.; Xue, N.; Liu, Y.; Zhang, Z.; Zhang, K.; Zhang, J.; Zhang, Y.; Wang,Q.; Sheng, L.; Li, Y.; Lu, D.*; Chen, X.*; Xu,H.* A novel orally active microtubule destabilizing agent S-40 targets thecolchicine-binding site and shows potent antitumor activity. Cancer Lett. 2020, 495, 22-32.

(5) Dong, Y.#; Chen, J.#;Cui, Y.; Bao, L.; Xu, H.*Cp*RhIII-catalyzed sulfonamide directed ortho arene C–H carbenoidfunctionalization with pyridotriazoles. Org.Lett., 2020, 22, 772-775.

(6) Wang, L.; Yang, H.; Zang, C.;Dong, Y.; Shang, J.; Chen, J.; Wang, Y.; Liu, H.; Zhang, Z.; Xu, H.*; Bao, X.*; Zhang, D.* CXCR2antagonism promotes oligodendrocyte precursor cell differentiation and enhancesremyelination in a mouse model of multiple sclerosis. Neurobiol. Dis. 2020,134, 104630.

(7) Lin, S.#; Jin, J.#;Liu, Y.#; Tian, H.; Zhang, Y.; Fu, R.; Zhang, J.; Wang, M.; Du, T.;Ji, M.; Wu, D.; Zhang, K.; Sheng, L.; Li, Y.; Chen, X.*; Xu, H.* Discovery of 4-Methyl Quinazoline Based PI3K Inhibitors forthe Potential Treatment of Idiopathic Pulmonary Fibrosis. J. Med. Chem. 2019, 62, 8873-8879.

(8) Zhang, K.#; Lai, F.#;Lin, S.; Ji, M.; Zhang, J.; Zhang, Y.; Jin, J.; Fu, R.; Wu, D.; Tian, H.; Xue,N.; Sheng, L.; Zou, X.; Li, Y.; Chen, X.*; Xu,H.* Design, Synthesis and Biological Evaluation of 4-Methyl QuinazolineDerivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide3-Kinases and Histone Deacetylases. J.Med. Chem. 2019, 62, 6992-7014.

(9) Dong, Y.#; Zhang, X.#;Chen, J.; Zou, W.; Lin, S.; Xu, H.*Switching the site-selectivity of C–H activation in aryl sulfonamidescontaining strongly coordinating N-heterocycles. Chem. Sci., 2019, 10, 8744-8751.

(10) Dong, Y.; Chen, J.; Xu, H.* Rhodium(III)-catalyzedsulfonamide directed ortho C–H carbenoid functionalization via metal carbenemigratory insertion. Chem.Commun. 2019, 55, 2027-2030.

(11) Lin, S.#; Wang, C.#;Ji, M.; Wu, D.; Lv, Y.; Zhang, K.; Dong, Y.; Jin, J.; Chen, J.; Zhang, J.;Sheng, L.; Li, Y.; Chen, X.*; Xu, H.*Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as HighlyPotent Phosphatidylinositol 3-kinase Inhibitors for Cancer Treatment. J. Med. Chem. 2018, 61, 6087–6109.

(12) Dong, Y.#; Chen, J.#;Xu, H.* Rhodium(III)-catalyzeddirected amidation of unactivated C(sp3)–H bonds to afford 1,2-amino alcoholderivatives. Chem. Commun. 2018, 54, 11096-11099.

(13) Lin, S.#; Wang, C.#;Ji, M.; Wu, D.; Lv, Y.; Sheng, L.; Han, F.; Dong, Y.; Zhang, K.; Yang, Y.; Li,Y.; Chen, X.*; Xu, H.* Discovery ofnew thienopyrimidine derivatives as potent and orally efficaciousphosphoinositide 3-kinase inhibitors. Bioorg.Med. Chem. 2018, 26, 637-646.

(14) Xu, H.*; Lu, H.; Xu, Z.; Luan, L.; Li, C.; Xu, Y.; Dong, K.; Zhang,J.; Li, X.; Li, Y.; Gong, S.; Zhao, Y.; Liu, A.; Zhang, Y.; Zhang, W.; Cai, X.;Xiang, J.; Elliott, J. D.; Lin, X.* Discovery of CNS Penetrant CXCR2Antagonists for the Potential Treatment of CNS Demyelinating Disorders. ACS Med. Chem. Lett. 2016, 7, 397-402.

(15) Han, F.#; Lin, S.#;Liu, P.; Liu, X.; Tao, J.; Deng, X.; Yi, C.; Xu, H.* Discovery of a novel thienopyrimidine series as highlypotent and selective PI3K inhibitors. ACSMed. Chem. Lett. 2015, 6, 434-438.